Forte Biosciences, Inc. (FBRX) Stock Price & How to Invest

Forte Biosciences (NASDAQ: FBRX) is a Dallas-based clinical-stage biopharmaceutical company built around a single lead candidate, FB102, a proprietary anti-CD122 monoclonal antibody. CD122 sits on the interleukin-15 signaling pathway that helps drive the tissue-resident memory T cells implicated in several autoimmune diseases, which is why Forte is testing FB102 across a broad set of indications including celiac disease, non-segmental vitiligo, and alopecia areata. The company generates no product revenue and does not expect commercial sales for years, so it functions less like an operating business and more like a research program with a stock ticker attached.

The investment picture is almost entirely event-driven. FB102 has produced early Phase 1b signals (statistically significant vitiligo improvement at week 24 and positive gluten-challenge data in celiac disease) and won FDA Fast Track designation in celiac, and multiple readouts (Phase 2 celiac topline, plus Phase 1b vitiligo and alopecia areata) are expected during 2026. Against that, Forte burns roughly $20 million a quarter and posted a Q1 2026 net loss of about $22 million, funded by repeated equity raises that dilute existing holders. The result is a high-volatility, all-or-nothing profile: strong data can re-rate the shares sharply higher, while a trial miss or safety issue can erase much of the market value.

FBRX is a single-asset, pre-revenue biotech, so a failure or safety signal in FB102 could impair most of the company's value. There are no product sales and no expected revenue for years, meaning the valuation rests entirely on clinical probability and market sentiment rather than earnings. The company funds itself through repeated equity raises that dilute existing shareholders, and its cash burn runs roughly $20 million per quarter. The shares are highly volatile and have moved several hundred percent over a one-year window, which cuts both ways. Competition in vitiligo, alopecia areata, and celiac disease is intensifying, and larger, better-capitalized developers could reach the market first or with better data.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Forte Biosciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-commercial)
• Net loss (Q1 2026): ~$22.1M
• R&D expense (Q1 2026): ~$20.5M
• Cash (end Q1 2026): ~$58M
• April 2026 raise (gross): ~$172.5M
• Market cap: ~$450M

Standard valuation metrics like price-to-earnings do not apply because Forte has no revenue and posts consistent losses. The market prices FBRX on the perceived probability and payoff of FB102's autoimmune programs, so the stock reacts to trial data far more than to any financial line item. The April 2026 raise strengthened the cash position but added shares outstanding.

There are three common ways to get FBRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so FBRX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where FBRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

FBRX is a single-asset, pre-commercial biotech story where 2026 trial data, not revenue, sets the price.

Whether FBRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FBRX a buy?, and where the stock could go from here in the FBRX stock forecast.

For income investors, whether FBRX pays a dividend and how the payout looks is covered in does FBRX pay a dividend?